Polymerase chain reaction-based and Sanger gene sequencing-base assays were undertaken to assess the contribution of genetic polymorphism in GSTM1 and GSTP1 to the susceptibility of bladder cancer (Fig. 1). This evidence concerns the gene GSTP1 and urinary bladder carcinoma.